Roche Maximizes Clinical Value by Accelerating Emergency and Infectious Disease Diagnostics with POCT Technology

July 26, 2026

Roche Switzerland

Overview

Roche emphasizes that Point-of-Care Testing (POCT) maximizes its value in urgent care and infectious disease diagnostics, such as sepsis and COVID-19, by enabling rapid clinical decision-making. Advances in biosensors, miniaturized electronics, and microfluidics have propelled POCT’s evolution, allowing for high-precision, on-site diagnostic testing without reliance on central laboratories. This is expected to improve immediacy of patient care and significantly reduce time to treatment intervention.

In Depth

Key Findings

Roche highlights that Point-of-Care Testing (POCT) delivers its highest value in scenarios demanding rapid results for immediate clinical decision-making, particularly in emergency care for conditions like sepsis or infectious diseases such as COVID-19. Driven by advancements in biosensors, miniaturized electronics, and microfluidics, POCT devices can now perform highly accurate diagnostic tests at the patient’s bedside, circumventing the need for central laboratory processing. This capability promises to significantly reduce diagnostic turnaround times and improve patient outcomes by enabling quicker therapeutic interventions.

Technical and Clinical Details

The evolution of POCT is underpinned by sophisticated biosensors capable of detecting multiple biomarkers from minimal sample volumes within minutes. For instance, in sepsis cases, POCT devices can measure inflammatory markers and infection indicators rapidly, assisting clinicians in making prompt decisions regarding antimicrobial therapy. For infectious diseases like COVID-19, on-site detection of viral antigens or nucleic acids facilitates immediate isolation and contact tracing, contributing to disease containment. These devices also reduce the logistical complexities and costs associated with central laboratories, enhancing healthcare access in resource-limited or remote settings. The integration of advanced microfluidics ensures precise sample handling and reaction control, crucial for accuracy outside controlled lab environments.

Background and Industry Context

Recent pandemic experiences underscored the critical importance of rapid and decentralized diagnostic capabilities. POCT’s value has been re-emphasized across various care settings, including emergency departments, intensive care units, primary care, and even home use. Market analyses project substantial growth for the POCT sector in the coming years, with further expansion anticipated through integration with digital health technologies that enable real-time data sharing and AI-powered analytics. Leading diagnostics manufacturers like Roche are at the forefront of this trend, investing in the development of more user-friendly and highly accurate POCT solutions to meet escalating demand.

Strategic Significance and Outlook

POCT technology is poised for continuous evolution, transforming into more multifunctional and integrated diagnostic platforms. Future developments will likely focus on enhancing multiplex testing capabilities, creating even smaller and more portable devices, and achieving seamless integration with telehealth systems. This trajectory will elevate POCT’s strategic value beyond acute disease management to encompass chronic disease monitoring and preventive medicine, fundamentally reshaping healthcare delivery models globally. The ability to bring diagnostics closer to the patient not only improves efficiency but also empowers individuals and healthcare providers with timely, actionable health information.

Source: https://diagnostics.roche.com/global/en/lab-leaders/article/when-to-use-point-of-care-testing.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.